Chronic low-grade inflammation, a hallmark of advancing age termed inflammaging, has been implicated in
metabolic dysfunction. Senescence, a state of permanent cell cycle arrest associated with advancing age,
occurs in response to stressors such as telomere dysfunction, DNA damage, and oxidative stress, and leads to
the release of a host of inflammatory mediators including cytokines and chemokines. These secreted factors
are collectively termed the senescence associated secretory phenotype (SASP). One function of SASP is the
recruitment of immune cells to promote clearance of senescent cells from tissues. While increased senescent
burden in both solid organs (i.e.; liver, adipose tissue) and immune cells, also known as immunosenescence,
likely contributes to inflammaging, the interplay between the two, the mechanisms governing these processes,
and how they lead to metabolic dysfunction are poorly understood. Recently, we have demonstrated
substantial T cell and macrophage accumulation in the adipose and liver of old mice and found that depletion
of T cells in these mice reduces tissue inflammation and improves systemic metabolism. In addition to immune
cell accumulation, immunosenescence, particularly in the adaptive immune system, may also contribute to
age-related dysfunction by both reducing the ability of recruited immune cells to clear damaged cells from
tissues and by exacerbating local inflammation. Indeed, preliminary data suggest that treatment of old mice
with a known senolytic drug cocktail, dasatinib and quercetin (D&Q), reduces adipose tissue senescence and
SASP, improves metabolic function, as well as reduces T cell accumulation in adipose of aged mice. These
data implicate tissue senescence in the recruitment of immune cells, inflammaging, and metabolic dysfunction.
Here, we will elucidate the effects of aging on tissue and immune cell senescence, T cell/macrophage
accumulation, and inflammation, as well as how these interact to impair metabolic function in advancing age.